Taurine
Taurine is a sulfur-containing amino acid that stabilizes mitochondrial tRNA, supports cardiovascular and metabolic health, and declines 80% with age. Moderate-effect human RCTs for blood pressure, heart failure, insulin sensitivity, and endurance; flagship 2023 primate aging-reversal data awaiting replication.
Taurine scored 7.9 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Type: Conditionally-essential amino acid (sulfur-containing, endogenous + dietary).
Taurine is a sulfur-containing conditionally essential amino acid made from cysteine. Unlike the 20 proteinogenic amino acids, it carries a sulfonic acid group rather than a carboxyl group, so it never enters peptide bonds and accumulates in free cytosolic pools instead. Endogenous synthesis is modest (roughly 50 to 125 mg/day), dietary intake averages 40 to 400 mg/day in omnivores and under 20 mg/day in strict vegans, and urinary excretion tracks intake closely.
The molecule became a priority longevity target in 2023 when Singh and colleagues (Science) (Yadav lab, Columbia) showed blood taurine declines 80% across adult life in humans, rhesus macaques, and mice. Supplementing mice starting at 14 months extended median lifespan 10 to 12%, and rhesus monkeys supplemented for 3 months showed reversal of multiple aging hallmarks including reduced DNA damage, lower senescence markers, and improved bone density. The proposed driver is stabilization of mitochondrial tRNA at the wobble position, which collapses without adequate taurine and causes age-related mitochondrial mistranslation. Human endpoints (blood pressure, heart-failure ejection fraction, insulin sensitivity, sleep via GABA-A partial agonism, ergogenic capacity) come from earlier independent RCT literature.
Terminology
- AML / CML / MDS: Acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes. Blood and bone-marrow cancers.
- LVEF: Left ventricular ejection fraction. The percentage of blood pumped out of the heart's main chamber per beat. Normal is 55 to 70%; heart failure is typically under 40%.
- NYHA class: New York Heart Association functional classification for heart failure severity (I through IV).
- 6MWT: Six-minute walk test. Standardized measure of exercise capacity.
- HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. A fasting-glucose-and-insulin proxy for insulin sensitivity; lower is better.
- HbA1c: Glycated hemoglobin. A 2 to 3 month average of blood glucose levels.
- SBP: Systolic blood pressure (the top number).
- SMD: Standardized Mean Difference. A meta-analysis effect-size metric. Roughly 0.2 is small, 0.5 moderate, 0.8 large.
- NOAEL: No Observed Adverse Effect Level. The highest dose in an animal study with no adverse findings.
- OSL: Observed Safe Level. A human-intake threshold set by expert review of chronic supplementation data.
- SLC6A6 / TAUT: The sodium/chloride-dependent taurine transporter protein and its gene.
- BAAT: Bile Acid-CoA Amino Acid N-Acyltransferase. The liver enzyme that conjugates bile acids with taurine or glycine.
- RyR2: Ryanodine Receptor 2. A calcium-release channel in cardiac muscle.
- SR Ca2+: Sarcoplasmic reticulum calcium flux. The intracellular calcium cycling that drives cardiac contraction.
- GABA-A: Gamma-aminobutyric acid type A receptor. The main inhibitory neurotransmitter receptor in the brain; the target of benzodiazepines, alcohol, and many sleep agents.
- FAERS: FDA Adverse Event Reporting System. The public database of post-market safety reports for drugs and supplements.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | powder | 1.5-6 g/day split 2-3x | 1-6 g/day |
| oral | magnesium taurate | 500-2000 mg compound (100-400 mg taurine) | Community-default sleep and BP stack |
| oral | capsule 1g | 1-3 g/day | 1-3 g/day |
Protocols
Pre-Bed Sleep Mixed
- Dose
- 1-3 g, 30-60 min before sleep
- Frequency
- Nightly
- Duration
- Indefinite
GABA-A partial agonism plus cell-volume regulation. Stacks cleanly with magnesium glycinate 200-400 mg, glycine 3 g, apigenin 50 mg. Nick's default protocol.
CHF Clinical (Azuma 1992 Protocol) Clinical
- Dose
- 2 g three times daily (6 g/day total)
- Frequency
- Split t.i.d.
- Duration
- Minimum 4 weeks for LVEF endpoint; indefinite if tolerated
Requires cardiology supervision. Not a substitute for guideline-directed medical therapy. Azuma 1992 LVEF +13 points, Beyranvand 2011 6MWT +91 m.
Longevity Daily (Post-Singh Biohacker Dose) Mixed
- Dose
- 3-6 g/day split into 2-3 doses
- Frequency
- Daily
- Duration
- Indefinite
Anchored to Singh 2023 primate reversal arm via allometric scaling. Higher end (6 g) for adults over 50 with confirmed low urinary taurine.
Pre-Workout Ergogenic Clinical
- Dose
- 1-3 g, 60 min pre-session
- Frequency
- Training days
- Duration
- Ongoing
Waldron 2018 SMD +0.39 for time-to-exhaustion. Stacks with creatine 5 g, beta-alanine 3-5 g, caffeine 3-6 mg/kg.
How this score is calculated →
Upside (2.75 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 4.5 | 0.675 | |
| Evidence Quality | 25% | 4.0 | 1.000 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 4.0 | 0.600 | |
| Total | 3.750 |
Upside Rationale
Efficacy (3.5/5.0): Effect sizes are moderate but consistent across independent endpoints. Sun et al. 2016 pooled 7 RCTs (n=871) and found systolic BP fell 3.4 mmHg overall, with a 7.2 mmHg drop at 3 g/day in pre-hypertensive and stage-1 hypertensive subjects, a clinically meaningful change that would cut stroke risk roughly 15% if held chronically. Waldron et al. 2018 meta-analyzed ergogenic trials (n=217) and reported a pooled SMD of +0.39 for time-to-exhaustion, moderate by Cohen's convention and comparable to beta-alanine at equivalent loading. Azuma et al. 1992 ran a placebo-controlled RCT in congestive heart failure (n=58, 6 g/day x 4 weeks) and documented a 13 percentage-point absolute gain in left ventricular ejection fraction plus NYHA class improvement in 79% of treated patients. Beyranvand et al. 2011 reproduced this in CHF with a 91-meter gain on the 6-minute walk test (n=29, 1.5 g t.i.d. x 2 weeks). Ahmadian et al. 2017 in type 2 diabetics (3 g/day x 8 weeks, n=45) reduced HOMA-IR 18.4% and HbA1c 0.4 percentage points. The Singh 2023 lifespan data sit in animals, not yet humans, so efficacy is anchored to the human RCT endpoints above.
Breadth of Benefits (4.5/5.0): Taurine spans cardiovascular (BP, CHF ejection fraction, lipid profile via bile acid conjugation), metabolic (insulin sensitivity, HbA1c, adiposity), neurological (GABA-A/glycine partial agonism, sleep latency, anxiolysis, neuroprotection in ischemia via glutamate excitotoxicity buffering), hepatic (NAFLD markers improve in multiple RCTs via BAAT-pathway bile acid conjugation), ophthalmological (retinal photoreceptor integrity, the original taurine-deficiency phenotype in cats), immune (chloramine-mediated quenching of neutrophil oxidative burst), musculoskeletal (ergogenic plus muscle cramp reduction), and geroscience (Singh 2023 lifespan plus healthspan hallmarks via mitochondrial tRNA stability). The mechanism set is unusually broad: osmoregulation in heart and brain, RyR2 stabilization and SR Ca2+ modulation underlying the heart-failure ejection-fraction data, bile-acid conjugation, mt-tRNA wobble-position stability, and partial agonism at GABA-A and glycine receptors. Few molecules touch this many organ systems with RCT-grade human evidence in each. This is the strongest upside dimension in the scorecard.
Evidence Quality (4.0/5.0): Multiple independent meta-analyses (Sun 2016 BP n=871, Waldron 2018 ergogenic n=217, Guan 2020 lipids, Chen 2016 CHF) covering 20+ RCTs. The Singh 2023 Science paper is a flagship mechanistic plus rodent lifespan plus non-human primate reversal study from a top-tier lab, though it is not yet replicated by a second independent group at equivalent scale. Human long-term RCTs exceeding 24 weeks remain scarce, and several metabolic trials have small n (20-60). Evidence does not reach creatine's 4.5 tier because the largest human trials are under 12 weeks and the longevity claim currently rests on a single primate arm. Still substantially stronger than the median supplement.
Speed of Onset (3.5/5.0): Acute effects are measurable within hours for sleep onset (GABA-A partial agonism; consistent with Kong 2006 and Wu/Prentice 2010 receptor-binding work). BP reductions begin within 1-2 weeks (Fujita 1987). CHF ejection fraction gains take 2-4 weeks (Azuma 1992). HOMA-IR and HbA1c changes require 8 weeks minimum (Ahmadian 2017). Mitochondrial tRNA remodeling likely takes months to peak. Split dosing is required for chronic endpoints because plasma half-life is approximately 1 hour.
Durability (2.5/5.0): Benefits depend on continued intake. Plasma taurine normalizes within 48-72 hours of cessation. Tissue stores deplete over 2-8 weeks depending on organ and baseline diet. BP and HOMA-IR effects reverse on washout in crossover trials. The Singh 2023 mitochondrial tRNA stability is a continuous-input phenomenon, not a one-time reset. This is the weakest upside dimension and the reason Durability anchors at 2.5 rather than creatine's 4.5.
Bioindividuality Upside (4.0/5.0): Responder prediction is unusually tractable. Vegans and vegetarians show the largest absolute urinary taurine deficits (Laidlaw 1988) and the most consistent subjective response. Age over 40 predicts larger gains per the Singh 2023 age-dependent plasma decline curve. Hypertensives respond more than normotensives (Sun 2016 subgroup: -7.2 mmHg vs -3.4 mmHg). CHF patients with LVEF under 50% respond more than preserved-EF patients (Azuma 1992). Diabetics with HbA1c above 7% respond more than well-controlled patients (Ahmadian 2017). Key genes: CSAD (synthesis capacity), SLC6A6 (the taurine transporter), BAAT (bile conjugation).
Downside (0.23 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.3 | 0.390 | |
| Side Effect Profile | 15% | 1.3 | 0.195 | |
| Financial Cost | 5% | 1.2 | 0.060 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 1.2 | 0.060 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.180 | |||
| Harm subtotal × 1.4 | 1.379 | |||
| Opportunity subtotal × 1.0 | 0.195 | |||
| Combined downside | 1.574 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.234 |
Downside Rationale
Safety Risk (1.3/5.0): Extensive safety data across food-additive use, energy-drink consumption (billions of servings), and supplementation trials to 6 g/day for months. NOAEL in chronic rat feeding studies is 1 g/kg body weight/day (Shao & Hathcock 2008). Norwegian VKM 2023 observed-safe-level ~100 mg/kg bw/day. No established human UL. Two meaningful contraindications: end-stage renal disease / dialysis is an absolute contraindication, and lithium is a relative contraindication requiring serum monitoring (taurine reduces renal lithium clearance). A 2025 Nature paper reported AML/CML/MDS cells scavenge taurine from bone marrow osteolineage cells via SLC6A6; this is a tumor-microenvironment finding in active blood cancers, not a dietary supplementation signal for healthy users, but constitutes an additional contraindication for anyone with active AML, CML, or MDS.
Side Effect Profile (1.3/5.0): Clinical-trial side-effect rates are placebo-equivalent at 1-3 g/day. Single doses above 6 g can produce mild transient GI symptoms (nausea, loose stool). Subjective reports of vivid dreams at bedtime doses >2 g, consistent with GABA-A partial agonism. Very rare reports of mild BP over-correction in already-normotensive individuals stacking with other antihypertensive protocols. No hepatotoxicity signal, no renal function impairment in healthy subjects across RCTs to 3 g/day x 12 weeks.
Financial Cost (1.2/5.0): Bulk taurine powder runs $0.05-0.15 per 1 g serving. USP/NSF-tested options under $0.20/day at 3 g. Magnesium taurate combinations run higher per mg of taurine but stack two useful molecules. Not a meaningful budget line item.
Time/Effort Burden (1.5/5.0): Split dosing is genuinely required for chronic endpoints because plasma half-life is ~1 hour. This is a real, if minor, burden above creatine's single daily dose. A pre-bed protocol for sleep is trivial. A BP/metabolic protocol requires 2-3 daily doses. Powder is neutral-to-mildly-sour in water; capsules are bulky at 1 g each.
Opportunity Cost (1.2/5.0): Stacks cleanly with creatine, magnesium (magnesium taurate is the community-default form for sleep and BP), berberine, omega-3, coenzyme Q10, and alpha-lipoic acid. No meaningful nutrient crowding.
Dependency / Withdrawal (1.0/5.0): No tolerance, no adaptation, no withdrawal syndrome, no rebound. Plasma taurine simply returns to baseline on cessation.
Reversibility (1.0/5.0): Fully reversible. All measured endpoints (BP, HOMA-IR, LVEF in CHF, sleep quality) normalize within weeks of cessation. No permanent changes documented.
Verdict
✅ Best for: Adults over 40 facing the Singh-2023 plasma-taurine decline curve. Hypertensives at SBP 130-150 mmHg seeking non-pharmaceutical BP support (Sun 2016 predicts -7.2 mmHg at 3 g/day). Congestive heart failure patients adjunctively (Azuma 1992 LVEF +13 points; Beyranvand 2011 6MWT +91 m). Type 2 diabetics not yet on glucose-lowering polypharmacy (Ahmadian 2017 HOMA-IR -18.4%). Vegans and vegetarians (conditionally essential; urinary taurine one-third of omnivores per Laidlaw 1988). Endurance athletes seeking a cheap legal ergogenic with moderate effect size (Waldron 2018 SMD +0.39, n=217). Sleep-optimizers needing a non-sedating GABAergic adjunct. Biohackers layering mitochondrial protocols where taurine covers the mt-tRNA stability axis that NAD+ precursors, urolithin A, CoQ10, and creatine miss.
❌ Avoid if: Active AML, CML, or MDS (per the 2025 Nature finding, paused until human clinical data clarifies risk). End-stage renal disease or dialysis (absolute contraindication). On lithium (relative contraindication; requires nephrology and psychiatry coordination with serum monitoring). Already on multiple antihypertensives with SBP under 110 (additive BP reduction risk). Pregnant or nursing without clinician guidance (safety data are thin despite no signal).
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Cardiovascular | 9.0 | Sun 2016 meta SBP -7.2 mmHg at 3 g/day in hypertensives; Azuma 1992 CHF LVEF +13 pts; Beyranvand 2011 6MWT +91 m |
| ✅ Sleep Quality | 8.5 | GABA-A and glycine partial agonism; community-confirmed pre-bed effect at 1-3 g; Kong 2006 and Wu/Prentice 2010 receptor-binding work |
| ✅ Metabolic Health | 8.0 | Ahmadian 2017 T2D n=45 HOMA-IR -18.4%, HbA1c -0.4% at 3 g/day x 8 weeks |
| ✅ Mitochondrial | 8.0 | Singh 2023 Science paper: mt-tRNA wobble-modification stabilization via 5-taurinomethyluridine; core aging mechanism |
| 💪 Longevity / Lifespan | 7.8 | Singh 2023: +10-12% median lifespan in mice (n=250/sex); primate aging-hallmark reversal after 3 months supplementation |
| 💪 Endurance / Cardio | 7.5 | Waldron 2018 meta SMD +0.39 time-to-exhaustion (n=217); comparable to beta-alanine at equivalent loading |
| 💪 Blood Sugar / Glycemic Control | 7.5 | Ahmadian 2017 HbA1c -0.4%; HOMA-IR -18.4% at 3 g/day x 8 weeks |
| 💪 Anti-Inflammatory | 7.0 | Taurine chloramine quenches HOCl at neutrophil oxidative burst sites; NAFLD ALT/AST reductions in multiple RCTs |
| 💪 Neuroprotection | 7.0 | Glutamate excitotoxicity buffering; ischemia animal models; partial GABA-A/glycine agonism in human brain |
| 👍 Liver / Detoxification | 6.8 | Multiple RCTs show ALT/AST improvements in NAFLD; bile-acid conjugation mechanism via BAAT pathway |
| 👍 Strength / Power | 6.5 | Waldron 2018 SMD +0.39 ergogenic effect; muscle cramp reduction community reports |
| 👍 Cognition / Focus | 6.5 | Indirect via mitochondrial energy support and cerebral osmoregulation; no direct cognition RCTs |
| 👍 Antioxidant / Oxidative Stress | 6.5 | Taurine chloramine and mitochondrial ROS buffering; well-characterized mechanism |
| 👍 Recovery / Repair | 6.3 | Reduced DOMS markers post-exercise; oxidative stress quenching |
| 👍 Anxiety | 6.0 | GABA-A partial agonism (Kong 2006 rodent); community reports consistent but human RCTs thin |
| 👍 Eye / Vision Health | 6.0 | Retinal photoreceptor integrity (the cat-deficiency phenotype); mostly preventive |
| ⚖️ Body Composition / Fat Loss | 5.5 | Indirect via training capacity; no direct fat-loss signal |
| ⚖️ Immune Function | 5.5 | Taurine chloramine modulation; no hard clinical endpoint data |
| ⚖️ HRV / Vagal Tone / Autonomic Balance | 5.5 | Indirect via GABA-A and cardiac autonomic modulation; limited direct data |
| ⚖️ Bone / Joint Health | 5.3 | Singh 2023 primate bone-density improvement; human data limited |
| ⚖️ Mood / Emotional Regulation | 5.0 | GABAergic signal; no depression RCTs |
| ⚖️ Fertility (Male) | 5.0 | Sperm motility improvements in small trials; thin evidence base |
| ○ Skin / Beauty | 4.0 | Antioxidant mechanism plausible; no direct skin RCTs |
| ○ Pregnancy Safety | 3.5 | Known fetal developmental role; supplementation RCTs insufficient for explicit recommendation |
Frequently Asked Questions
What does taurine actually do in the body?
Taurine stabilizes mitochondrial tRNA at the wobble position via 5-taurinomethyluridine formation, the core mechanism behind Singh et al. 2023's +10 to 12% mouse lifespan result (n=250 per sex). Four supporting mechanisms extend the benefit set: osmoregulation of cardiac and brain cells (why taurine-depleted cats develop dilated cardiomyopathy within months), bile acid conjugation via the BAAT pathway, cardiac calcium handling through RyR2 stabilization and sarcoplasmic-reticulum flux, and weak partial agonism at GABA-A and glycine receptors. This unusual mechanistic breadth is why one molecule touches cardiovascular, metabolic, neurological, hepatic, ophthalmological, and longevity endpoints in independent RCTs.
How much taurine should I take and when?
Effective clinical range is 1.5 to 6 g/day split across 2 to 3 doses, with 3 g/day the anchor for blood-pressure (−7.2 mmHg SBP, Sun 2016) and insulin-sensitivity (−18.4% HOMA-IR, Ahmadian 2017) effects. Plasma half-life is about 1 hour, so a single daily bolus is ineffective for chronic endpoints. For sleep specifically, 1 to 3 g taken 30 to 60 minutes before bed is the community default and matches the GABA-A and glycine receptor agonism window. Longevity-stack dosing at 3 to 6 g/day is an allometric scaling estimate from the Singh 2023 primate arm and is not yet validated in human outcomes data.
Does taurine really extend lifespan in humans?
No human lifespan RCT exists yet; the longevity case rests on one flagship animal study plus mechanistic plausibility. Singh et al. 2023 (Science) demonstrated 10 to 12% median lifespan extension in mice starting at 14 months (n=250 per sex) and reversal of multiple aging hallmarks in rhesus macaques after 3 months of supplementation. Reduced DNA damage, lower senescence markers, improved bone density. Human evidence is limited to surrogate markers with moderate effect sizes: blood pressure, HOMA-IR, LVEF in heart failure, sleep latency, time-to-exhaustion. The 80% age-related plasma decline is consistent across humans, macaques, and mice, which strengthens the mechanistic case but does not substitute for a hard human outcomes trial.
Is taurine safe for long-term daily use?
Yes for healthy adults at up to 3 g/day; the safety profile is among the best of any longevity supplement. Chronic rat NOAEL is 1 g/kg bodyweight/day; human observed-safe-level is 3 g/day per the Shao & Hathcock 2008 expert panel. Clinical trials up to 6 g/day for 8 to 12 weeks show placebo-equivalent side-effect rates with no hepatotoxicity or renal-function impairment in healthy subjects. Energy-drink data (billions of servings) reinforces the signal. The three exceptions are: end-stage renal disease, concurrent lithium therapy, and active AML, CML, or MDS (per Sharma et al. 2025 Nature on bone-marrow microenvironment scavenging). These are detailed in the "Who should avoid" section.
Who should avoid taurine?
Five contraindications, in descending order of evidence strength. End-stage renal disease or dialysis is absolute. Impaired clearance creates unpredictable plasma accumulation. Concurrent lithium therapy is relative and requires serum-level monitoring because taurine reduces renal lithium clearance. Active AML, CML, or MDS is a new contraindication since Sharma et al. 2025 showed these malignant cells scavenge taurine from the bone-marrow osteolineage niche via SLC6A6. Concurrent multi-drug antihypertensive therapy with SBP already under 110 mmHg risks additive BP reduction. Pregnancy and lactation are relative contraindications not because of an adverse signal but because supplementation RCTs in these populations are too thin to justify recommendation.
Taurine powder vs magnesium taurate: which form should I buy?
Bulk taurine powder at $0.05 to $0.15 per gram is the cost leader and the only practical option for protocols requiring 3 g/day or more; the 6 g CHF clinical dose would cost about $30/month in capsules but under $10/month in powder. Magnesium taurate capsules deliver 100 to 400 mg of elemental taurine per 1000 mg capsule, fine for sleep and BP stacking where you'd already take 300 to 400 mg of magnesium, but too dilute for longevity-range dosing. Plain capsules (1 g) sit between the two on cost and convenience. Absorption is >80% via the SLC6A6 transporter regardless of form. USP or NSF third-party testing matters more than form.
How quickly should I expect to feel effects?
Sleep effects are acute (hours, not weeks) at a 1 to 3 g pre-bed dose via GABA-A and glycine partial agonism. Blood pressure reductions begin within 1 to 2 weeks of consistent split dosing (Fujita 1987: −9 mmHg SBP at 6 g/day x 7 days). Heart-failure ejection-fraction gains require 2 to 4 weeks at 6 g/day t.i.d. (Azuma 1992: +13 percentage points LVEF). HOMA-IR and HbA1c changes need at least 8 weeks (Ahmadian 2017). Mitochondrial tRNA remodeling, the Singh 2023 longevity axis, is a continuous-input phenomenon likely measured in months, and reverses within weeks of cessation as tissue stores deplete.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension changes | New score |
|---|---|---|
| Human lifespan/healthspan RCT replicates Singh 2023 at n>500 over 5 years | Efficacy 3.5→4.5, Evidence 4.0→4.5, Durability 2.5→3.5 | 8.6 / 10 ✅ Top-tier |
| Second independent primate aging-reversal study fails to replicate | Efficacy 3.5→3.0, Evidence 4.0→3.5 | 7.5 / 10 💪 Strong recommend |
| Large CHF outcomes trial (>1,000 pts) shows mortality reduction | Breadth 4.5→4.8, Efficacy 3.5→4.2 | 8.3 / 10 ✅ Top-tier |
| Long-term safety signal emerges in 24+ month trial | Safety 1.3→2.5, Evidence 4.0→3.8 | 7.2 / 10 💪 Strong recommend |
| FDA or EFSA sets a human UL below 3 g/day | Safety 1.3→2.0, Effort 1.5→2.5 | 7.5 / 10 💪 Strong recommend |
| Confirmed human data on AML/CML/MDS microenvironment pathway showing dietary-range risk | Safety 1.3→3.0 | 7.0 / 10 💪 Strong recommend |
Key Evidence Sources
- Singh P, Gollapalli K, Mangiola S et al. 2023, Science. Taurine deficiency as a driver of aging. 80% plasma decline across adult life; +10-12% mouse median lifespan (n=250/sex); rhesus monkey aging-hallmark reversal; mitochondrial tRNA stability mechanism. Yadav lab, Columbia. — Flagship translational paper anchoring the longevity case
- Sun Q, Wang B, Li Y et al. 2016, Hypertension. Meta-analysis of 7 RCTs (n=871). SBP -3.4 mmHg overall, -7.2 mmHg at 3 g/day in hypertensives. — Primary BP meta-analysis
- Waldron M, Patterson SD, Tallent J, Jeffries O. 2018, Sports Medicine. Ergogenic meta-analysis (n=217). Pooled SMD +0.39 for time-to-exhaustion. — Ergogenic evidence anchor
- Azuma J, Sawamura A, Awata N et al. 1992, Clinical Cardiology. CHF RCT n=58, 6 g/day x 4 weeks. LVEF +13 percentage points; NYHA class improved in 79%. — Landmark CHF clinical trial
- Beyranvand MR, Khalafi MK, Roshan VD et al. 2011, Acta Cardiologica. CHF n=29. 6-minute walk test +91 m at 1.5 g t.i.d. x 2 weeks. — CHF functional replication
- Ahmadian M, Roshan VD, Aslani E, Stannard SR. 2017, Journal of Diabetes & Metabolic Disorders. T2D n=45, 3 g/day x 8 weeks. HOMA-IR -18.4%; HbA1c -0.4 percentage points. — T2D metabolic RCT
- Laidlaw SA, Shultz TD, Cecchino JT, Kopple JD. 1988, American Journal of Clinical Nutrition. Urinary taurine in vegans one-third of omnivores; established conditionally essential status. — Conditionally-essential classification
- Shao A, Hathcock JN. 2008, Regulatory Toxicology and Pharmacology. OSL panel: 3 g/day chronic observed-safe-level; rat NOAEL 1 g/kg/day. — OSL safety framework
- Sharma et al. 2025, Nature. SLC6A6-mediated taurine scavenging by AML/CML/MDS cells from bone marrow osteolineage niche. Tumor-microenvironment finding; contraindication scope limited to active disease. — 2025 leukemia contraindication paper
- Wu JY, Prentice H. 2010, Journal of Biomedical Science. Taurine partial agonism at GABA-A and glycine receptors; mechanism paper for sleep and anxiolytic effects. — Sleep and anxiolytic mechanism
- Kong WX, Chen SW, Li YL et al. 2006, Pharmacology Biochemistry and Behavior. Anxiolytic and sleep-promoting effects via GABAergic mechanism in rodent models. — Anxiolytic preclinical support
- Fujita T, Ando K, Noda H et al. 1987, Circulation. Early taurine-BP RCT in borderline hypertensives; SBP -9 mmHg at 6 g/day x 7 days. — Earliest BP RCT evidence
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.750 − 0.234 = 2.516
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((2.516 + 7) / 12) × 10 = 7.9 / 10
Further reading
The Best Mitochondrial Support Supplements to Boost Energy, ATP, & Cellular Health
Looking to boost your cellular energy, resilience, and longevity? The right nutrients can supercharge mitochondrial function. In this guide, we review the best mitochondria…
Is Mitochondrial Dysfunction Driving Your Fatigue & Anxiety?
Why do high performers suddenly hit a wall of burnout? Dr. Scott Sherr breaks down the “sympathetic spiral of doom,” showing how nervous system…
